Phase I Trial Shows Promise for Cimaglermin in Heart Failure

Share this content:
Phase I Trial Shows Promise for Cimaglermin in Heart Failure
Phase I Trial Shows Promise for Cimaglermin in Heart Failure

WEDNESDAY, Dec. 28, 2016 (HealthDay News) -- The recombinant growth factor, cimaglermin alfa, may enhance cardiac function in left ventricular systolic dysfunction (LVSD), according to a study published in the Dec. 1 issue of JACC: Basic to Translational Science.

Daniel J. Lenihan, M.D., from Vanderbilt University in Nashville, Tenn., and colleagues examined the safety, tolerability, and exploratory efficacy of intravenous infusion of cimaglermin alfa in a first-in-human, phase 1 single ascending dose study involving 40 patients with heart failure and LVSD.

The researchers found that cimaglermin treatment was generally well tolerated in these patients on optimal guideline-directed medical therapy, except for transient nausea and headache. At the highest planned dose, dose-limiting toxicity was noted. A dose-dependent improvement was seen in left ventricular ejection fraction, which lasted 90 days after infusion.

"Thus, cimaglermin is a potential therapy to enhance cardiac function in LVSD and warrants further investigation," the authors write.

Several authors disclosed financial ties to pharmaceutical companies, including Acorda Therapeutics, which is developing cimaglermin alfa and funded the study.

Full Text
Editorial

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters


More in Home

USPSTF Urges Abuse Screening for Reproductive-Aged Women

USPSTF Urges Abuse Screening for Reproductive-Aged Women

Evidence lacking for assessing balance of benefits, harms of screening for abuse of seniors, vulnerable

Five-Day Nitrofurantoin Beats Single-Dose Fosfomycin for UTI

Five-Day Nitrofurantoin Beats Single-Dose Fosfomycin for UTI

Increased likelihood of clinical and microbiological resolution for uncomplicated UTI in women

Exercise Intervention Doesn't Improve Walking Ability in PAD

Exercise Intervention Doesn't Improve Walking Ability in PAD

Smaller mean change from baseline to follow-up in 6-minute walking distance with exercise intervention

is free, fast, and customized just for you!

Already a member?

Sign In Now »